 Brian Lee
Concepts (353)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 41 | 2023 | 243 | 5.670 |
Why?
| | Humans | 103 | 2024 | 6896 | 2.520 |
Why?
| | Child | 76 | 2024 | 3364 | 2.500 |
Why?
| | Respiratory Tract Infections | 9 | 2024 | 85 | 2.420 |
Why?
| | Retrospective Studies | 45 | 2024 | 1296 | 1.900 |
Why?
| | Hospitals, Pediatric | 16 | 2021 | 187 | 1.880 |
Why?
| | Enterovirus Infections | 3 | 2023 | 37 | 1.740 |
Why?
| | Picornaviridae Infections | 3 | 2023 | 21 | 1.710 |
Why?
| | Drug Utilization | 4 | 2020 | 15 | 1.650 |
Why?
| | Infant | 35 | 2023 | 1446 | 1.630 |
Why?
| | Hospitalization | 10 | 2023 | 210 | 1.620 |
Why?
| | Patient Readmission | 5 | 2023 | 68 | 1.600 |
Why?
| | Enterovirus | 2 | 2023 | 12 | 1.580 |
Why?
| | Parechovirus | 2 | 2023 | 20 | 1.560 |
Why?
| | Inappropriate Prescribing | 10 | 2023 | 27 | 1.520 |
Why?
| | Anti-Infective Agents | 7 | 2023 | 21 | 1.380 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 30 | 1.380 |
Why?
| | Child, Preschool | 37 | 2024 | 1569 | 1.350 |
Why?
| | Male | 45 | 2024 | 3337 | 1.290 |
Why?
| | Female | 44 | 2024 | 3525 | 1.250 |
Why?
| | Emergency Service, Hospital | 11 | 2023 | 130 | 1.230 |
Why?
| | United States | 24 | 2023 | 669 | 1.140 |
Why?
| | Asthma | 7 | 2024 | 157 | 1.140 |
Why?
| | Ambulatory Care | 11 | 2022 | 45 | 1.110 |
Why?
| | Cross Infection | 4 | 2019 | 12 | 1.080 |
Why?
| | Inpatients | 4 | 2021 | 44 | 1.000 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2019 | 14 | 0.930 |
Why?
| | Practice Patterns, Physicians' | 10 | 2023 | 85 | 0.900 |
Why?
| | Norovirus | 1 | 2023 | 7 | 0.880 |
Why?
| | Rotavirus Vaccines | 1 | 2023 | 14 | 0.880 |
Why?
| | Rotavirus | 1 | 2023 | 18 | 0.880 |
Why?
| | Rotavirus Infections | 1 | 2023 | 20 | 0.880 |
Why?
| | Streptococcal Infections | 3 | 2022 | 19 | 0.870 |
Why?
| | Gastroenteritis | 1 | 2023 | 28 | 0.860 |
Why?
| | Adolescent | 31 | 2024 | 2197 | 0.860 |
Why?
| | Coinfection | 1 | 2022 | 7 | 0.830 |
Why?
| | Infant, Newborn | 18 | 2023 | 816 | 0.780 |
Why?
| | Pharyngitis | 4 | 2023 | 16 | 0.780 |
Why?
| | Hospital Mortality | 3 | 2023 | 22 | 0.770 |
Why?
| | Skin | 2 | 2024 | 15 | 0.740 |
Why?
| | Risk Factors | 12 | 2024 | 487 | 0.740 |
Why?
| | Drug Prescriptions | 5 | 2020 | 20 | 0.720 |
Why?
| | Patient Acuity | 1 | 2019 | 7 | 0.700 |
Why?
| | Drug Eruptions | 1 | 2019 | 3 | 0.690 |
Why?
| | Pediatrics | 7 | 2020 | 186 | 0.680 |
Why?
| | Clostridium Infections | 1 | 2019 | 7 | 0.680 |
Why?
| | Schools | 3 | 2024 | 56 | 0.660 |
Why?
| | Ambulatory Care Facilities | 7 | 2023 | 36 | 0.660 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 9 | 0.650 |
Why?
| | Length of Stay | 10 | 2023 | 233 | 0.640 |
Why?
| | Medicaid | 4 | 2020 | 38 | 0.590 |
Why?
| | Listeriosis | 1 | 2016 | 1 | 0.540 |
Why?
| | Streptococcus agalactiae | 1 | 2016 | 1 | 0.540 |
Why?
| | Infection Control | 1 | 2016 | 7 | 0.530 |
Why?
| | Surveys and Questionnaires | 8 | 2023 | 274 | 0.530 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2021 | 38 | 0.520 |
Why?
| | Outpatients | 5 | 2023 | 27 | 0.510 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 35 | 0.470 |
Why?
| | Quality Improvement | 6 | 2021 | 60 | 0.470 |
Why?
| | Adult | 11 | 2024 | 1181 | 0.460 |
Why?
| | Risk Adjustment | 2 | 2021 | 5 | 0.430 |
Why?
| | Otitis Media | 2 | 2023 | 8 | 0.430 |
Why?
| | Racism | 2 | 2022 | 8 | 0.410 |
Why?
| | Pandemics | 2 | 2023 | 82 | 0.400 |
Why?
| | Cross-Sectional Studies | 10 | 2024 | 336 | 0.390 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2023 | 11 | 0.380 |
Why?
| | Databases, Factual | 7 | 2020 | 108 | 0.380 |
Why?
| | Prevalence | 6 | 2023 | 146 | 0.370 |
Why?
| | Urinary Tract Infections | 2 | 2023 | 21 | 0.370 |
Why?
| | Penicillins | 2 | 2022 | 8 | 0.370 |
Why?
| | Pharmacy Service, Hospital | 3 | 2020 | 8 | 0.360 |
Why?
| | Communication | 5 | 2022 | 46 | 0.350 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.350 |
Why?
| | Bacterial Infections | 2 | 2021 | 27 | 0.340 |
Why?
| | Influenza, Human | 2 | 2020 | 68 | 0.320 |
Why?
| | Cohort Studies | 6 | 2020 | 289 | 0.310 |
Why?
| | Drug Utilization Review | 3 | 2018 | 6 | 0.310 |
Why?
| | Internship and Residency | 2 | 2020 | 39 | 0.310 |
Why?
| | Bacteremia | 2 | 2019 | 25 | 0.300 |
Why?
| | Health Care Costs | 2 | 2019 | 33 | 0.300 |
Why?
| | Disease Outbreaks | 2 | 2023 | 29 | 0.290 |
Why?
| | Treatment Outcome | 6 | 2019 | 622 | 0.280 |
Why?
| | Child, Hospitalized | 3 | 2022 | 26 | 0.280 |
Why?
| | Students | 2 | 2024 | 34 | 0.280 |
Why?
| | Guideline Adherence | 2 | 2018 | 36 | 0.270 |
Why?
| | Seasons | 2 | 2023 | 35 | 0.270 |
Why?
| | Aged | 4 | 2021 | 378 | 0.270 |
Why?
| | Incidence | 4 | 2023 | 133 | 0.260 |
Why?
| | Time Factors | 4 | 2020 | 250 | 0.260 |
Why?
| | Giardiasis | 2 | 2018 | 2 | 0.260 |
Why?
| | Neoplasms | 2 | 2018 | 128 | 0.260 |
Why?
| | Vaccination | 5 | 2022 | 71 | 0.250 |
Why?
| | Risk Assessment | 3 | 2019 | 137 | 0.250 |
Why?
| | Drug Hypersensitivity | 2 | 2022 | 19 | 0.250 |
Why?
| | Acute Disease | 5 | 2023 | 79 | 0.240 |
Why?
| | Chickenpox | 1 | 2004 | 1 | 0.240 |
Why?
| | Herpesvirus 3, Human | 1 | 2004 | 1 | 0.240 |
Why?
| | Chickenpox Vaccine | 1 | 2004 | 2 | 0.240 |
Why?
| | Prader-Willi Syndrome | 1 | 2024 | 1 | 0.240 |
Why?
| | Puberty, Precocious | 1 | 2024 | 2 | 0.240 |
Why?
| | Air Pollution | 1 | 2024 | 4 | 0.240 |
Why?
| | Insurance | 1 | 2024 | 2 | 0.240 |
Why?
| | Young Adult | 6 | 2022 | 647 | 0.240 |
Why?
| | Curriculum | 2 | 2022 | 22 | 0.240 |
Why?
| | Environmental Exposure | 1 | 2024 | 29 | 0.230 |
Why?
| | Wrist Injuries | 1 | 2023 | 1 | 0.230 |
Why?
| | Scaphoid Bone | 1 | 2023 | 1 | 0.230 |
Why?
| | Hand Injuries | 1 | 2023 | 2 | 0.230 |
Why?
| | Histamine | 1 | 2024 | 13 | 0.230 |
Why?
| | Missouri | 5 | 2024 | 81 | 0.230 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 7 | 0.230 |
Why?
| | Fractures, Bone | 1 | 2023 | 34 | 0.230 |
Why?
| | Otitis Media with Effusion | 1 | 2023 | 3 | 0.220 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 52 | 0.220 |
Why?
| | Prospective Studies | 5 | 2024 | 525 | 0.220 |
Why?
| | Hypersensitivity | 1 | 2024 | 56 | 0.220 |
Why?
| | Feces | 1 | 2023 | 37 | 0.220 |
Why?
| | General Surgery | 2 | 2020 | 19 | 0.220 |
Why?
| | Enterovirus D, Human | 1 | 2023 | 25 | 0.220 |
Why?
| | Liver Diseases | 1 | 2023 | 18 | 0.210 |
Why?
| | Vaccines | 1 | 2022 | 17 | 0.210 |
Why?
| | Pneumonia, Aspiration | 1 | 2022 | 8 | 0.210 |
Why?
| | Fever | 2 | 2019 | 26 | 0.200 |
Why?
| | Parents | 2 | 2021 | 157 | 0.200 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2019 | 15 | 0.200 |
Why?
| | Pneumonia | 1 | 2022 | 32 | 0.200 |
Why?
| | Patient Handoff | 1 | 2021 | 4 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2021 | 8 | 0.200 |
Why?
| | Ceftriaxone | 1 | 2021 | 13 | 0.190 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 6 | 0.190 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 8 | 0.190 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 21 | 0.190 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 8 | 0.190 |
Why?
| | DNA, Viral | 1 | 2020 | 13 | 0.180 |
Why?
| | Point-of-Care Systems | 1 | 2020 | 10 | 0.180 |
Why?
| | Video Recording | 1 | 2020 | 14 | 0.180 |
Why?
| | Influenza A virus | 1 | 2020 | 20 | 0.180 |
Why?
| | Patient Education as Topic | 1 | 2020 | 53 | 0.180 |
Why?
| | Intestinal Polyposis | 1 | 2019 | 7 | 0.170 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2019 | 6 | 0.170 |
Why?
| | Colonic Polyps | 1 | 2019 | 5 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2023 | 149 | 0.170 |
Why?
| | Administration, Cutaneous | 1 | 2019 | 4 | 0.170 |
Why?
| | Nurses | 2 | 2018 | 9 | 0.170 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2019 | 19 | 0.170 |
Why?
| | World Health Organization | 1 | 2019 | 8 | 0.170 |
Why?
| | Intubation, Gastrointestinal | 1 | 2019 | 20 | 0.170 |
Why?
| | Linear Models | 1 | 2019 | 56 | 0.170 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2024 | 65 | 0.170 |
Why?
| | Kansas | 3 | 2024 | 43 | 0.170 |
Why?
| | Causality | 1 | 2019 | 10 | 0.170 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 4 | 0.170 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2019 | 38 | 0.170 |
Why?
| | Pharmacovigilance | 1 | 2019 | 8 | 0.170 |
Why?
| | Endoscopy | 1 | 2019 | 14 | 0.170 |
Why?
| | Cefazolin | 1 | 2018 | 2 | 0.160 |
Why?
| | Oseltamivir | 1 | 2018 | 6 | 0.160 |
Why?
| | Enteral Nutrition | 1 | 2019 | 63 | 0.160 |
Why?
| | Critical Pathways | 1 | 2018 | 8 | 0.160 |
Why?
| | Albuterol | 1 | 2018 | 5 | 0.160 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2018 | 2 | 0.160 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.160 |
Why?
| | Preoperative Care | 1 | 2018 | 26 | 0.160 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 9 | 0.160 |
Why?
| | Bronchodilator Agents | 1 | 2018 | 11 | 0.160 |
Why?
| | Hospital Records | 1 | 2018 | 1 | 0.160 |
Why?
| | Rhinovirus | 1 | 2018 | 11 | 0.160 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 4 | 0.160 |
Why?
| | Disease Management | 1 | 2018 | 34 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2018 | 16 | 0.160 |
Why?
| | Anti-Asthmatic Agents | 1 | 2018 | 11 | 0.160 |
Why?
| | Decision Making | 1 | 2018 | 23 | 0.160 |
Why?
| | Psychometrics | 1 | 2018 | 30 | 0.160 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 30 | 0.160 |
Why?
| | Prescription Drug Overuse | 1 | 2018 | 1 | 0.160 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 1 | 0.160 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 10 | 0.160 |
Why?
| | Health Communication | 1 | 2018 | 4 | 0.160 |
Why?
| | Steroids | 1 | 2018 | 16 | 0.160 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2018 | 18 | 0.160 |
Why?
| | Survival Analysis | 1 | 2018 | 50 | 0.160 |
Why?
| | Information Dissemination | 1 | 2018 | 8 | 0.160 |
Why?
| | Bacteria | 1 | 2018 | 9 | 0.160 |
Why?
| | Nurse's Role | 1 | 2018 | 10 | 0.160 |
Why?
| | Middle Aged | 5 | 2021 | 608 | 0.160 |
Why?
| | Logistic Models | 4 | 2019 | 84 | 0.160 |
Why?
| | Electronic Health Records | 1 | 2018 | 64 | 0.150 |
Why?
| | Hepatitis C | 1 | 2017 | 4 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 50 | 0.150 |
Why?
| | Hospitals | 3 | 2023 | 36 | 0.150 |
Why?
| | Postoperative Complications | 1 | 2019 | 184 | 0.150 |
Why?
| | Substance-Related Disorders | 1 | 2017 | 26 | 0.150 |
Why?
| | Home Infusion Therapy | 1 | 2017 | 2 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2017 | 13 | 0.140 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 26 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2017 | 16 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2017 | 30 | 0.140 |
Why?
| | Benchmarking | 3 | 2023 | 11 | 0.140 |
Why?
| | Health Information Systems | 1 | 2016 | 5 | 0.140 |
Why?
| | Pancreatitis | 1 | 2016 | 8 | 0.140 |
Why?
| | Streptococcus | 1 | 2016 | 2 | 0.130 |
Why?
| | Interdisciplinary Communication | 1 | 2016 | 9 | 0.130 |
Why?
| | Patient Transfer | 1 | 2016 | 8 | 0.130 |
Why?
| | Cardiology | 1 | 2016 | 11 | 0.130 |
Why?
| | Health Education | 2 | 2020 | 26 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2015 | 13 | 0.130 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 37 | 0.130 |
Why?
| | Hospitalists | 1 | 2015 | 7 | 0.130 |
Why?
| | Medication Therapy Management | 1 | 2015 | 8 | 0.130 |
Why?
| | Minnesota | 3 | 2018 | 6 | 0.120 |
Why?
| | Acetamides | 1 | 2014 | 2 | 0.120 |
Why?
| | Oxazolidinones | 1 | 2014 | 2 | 0.120 |
Why?
| | Regression Analysis | 3 | 2019 | 52 | 0.120 |
Why?
| | Treatment Failure | 2 | 2022 | 16 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2021 | 151 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2019 | 199 | 0.110 |
Why?
| | Primary Health Care | 3 | 2018 | 42 | 0.110 |
Why?
| | Prescriptions | 2 | 2022 | 9 | 0.110 |
Why?
| | Practice Guidelines as Topic | 3 | 2018 | 108 | 0.100 |
Why?
| | Reference Standards | 1 | 2021 | 15 | 0.100 |
Why?
| | Program Evaluation | 3 | 2020 | 45 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 150 | 0.090 |
Why?
| | Streptococcus pyogenes | 2 | 2022 | 13 | 0.090 |
Why?
| | Homosexuality, Male | 1 | 2010 | 1 | 0.090 |
Why?
| | Unsafe Sex | 1 | 2010 | 2 | 0.090 |
Why?
| | Safe Sex | 1 | 2010 | 2 | 0.090 |
Why?
| | Health Promotion | 1 | 2010 | 39 | 0.090 |
Why?
| | HIV Infections | 1 | 2010 | 50 | 0.080 |
Why?
| | Age Distribution | 2 | 2019 | 31 | 0.080 |
Why?
| | Preventive Health Services | 1 | 2008 | 2 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2008 | 6 | 0.080 |
Why?
| | Hospital Charges | 2 | 2018 | 11 | 0.080 |
Why?
| | Comorbidity | 2 | 2019 | 56 | 0.080 |
Why?
| | Feedback | 2 | 2021 | 4 | 0.080 |
Why?
| | Child Health Services | 2 | 2020 | 24 | 0.080 |
Why?
| | Mass Screening | 1 | 2008 | 35 | 0.080 |
Why?
| | Recurrence | 2 | 2017 | 110 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 16 | 0.070 |
Why?
| | Risk | 2 | 2016 | 41 | 0.070 |
Why?
| | Colorado | 2 | 2018 | 9 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2019 | 33 | 0.060 |
Why?
| | Social Justice | 1 | 2024 | 2 | 0.060 |
Why?
| | Air Pollutants | 1 | 2024 | 12 | 0.060 |
Why?
| | Health Policy | 1 | 2004 | 14 | 0.060 |
Why?
| | Virus Diseases | 1 | 2024 | 16 | 0.060 |
Why?
| | Skin Pigmentation | 1 | 2024 | 2 | 0.060 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2024 | 7 | 0.060 |
Why?
| | Iontophoresis | 1 | 2024 | 7 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 51 | 0.060 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2023 | 3 | 0.060 |
Why?
| | Mexico | 1 | 2023 | 5 | 0.060 |
Why?
| | Casts, Surgical | 1 | 2023 | 1 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2018 | 304 | 0.060 |
Why?
| | Amoxicillin | 1 | 2023 | 4 | 0.060 |
Why?
| | Azithromycin | 1 | 2023 | 5 | 0.060 |
Why?
| | Biomarkers | 1 | 2024 | 136 | 0.060 |
Why?
| | Body Mass Index | 1 | 2024 | 157 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 53 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Prognosis | 1 | 2023 | 211 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 10 | 0.050 |
Why?
| | Bilirubin | 1 | 2023 | 26 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2023 | 33 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 15 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.050 |
Why?
| | Efficiency, Organizational | 1 | 2022 | 3 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2022 | 42 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 47 | 0.050 |
Why?
| | Skin Tests | 1 | 2022 | 19 | 0.050 |
Why?
| | Cities | 1 | 2022 | 10 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2022 | 19 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2022 | 9 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2022 | 39 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 14 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 2 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 8 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 25 | 0.050 |
Why?
| | Pilot Projects | 1 | 2021 | 120 | 0.050 |
Why?
| | Patient Discharge | 1 | 2021 | 57 | 0.050 |
Why?
| | ROC Curve | 1 | 2020 | 22 | 0.050 |
Why?
| | Immunization | 1 | 2020 | 25 | 0.050 |
Why?
| | Leadership | 1 | 2020 | 12 | 0.050 |
Why?
| | Safety | 1 | 2020 | 14 | 0.040 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 7 | 0.040 |
Why?
| | Colonoscopy | 1 | 2019 | 15 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 31 | 0.040 |
Why?
| | Gastric Acidity Determination | 1 | 2019 | 1 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 10 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 11 | 0.040 |
Why?
| | Midwestern United States | 1 | 2019 | 34 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 111 | 0.040 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 18 | 0.040 |
Why?
| | Probability | 1 | 2019 | 15 | 0.040 |
Why?
| | Sepsis | 1 | 2019 | 23 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2019 | 14 | 0.040 |
Why?
| | Hospital Costs | 1 | 2019 | 29 | 0.040 |
Why?
| | Washington | 1 | 2018 | 11 | 0.040 |
Why?
| | Translations | 1 | 2018 | 4 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 17 | 0.040 |
Why?
| | Metered Dose Inhalers | 1 | 2018 | 1 | 0.040 |
Why?
| | Reimbursement, Incentive | 1 | 2018 | 4 | 0.040 |
Why?
| | Patient Participation | 1 | 2018 | 15 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2018 | 24 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 17 | 0.040 |
Why?
| | Metabolic Diseases | 1 | 2018 | 11 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2018 | 33 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2018 | 18 | 0.040 |
Why?
| | Infant, Premature | 1 | 2019 | 85 | 0.040 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 7 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2018 | 38 | 0.040 |
Why?
| | Home Care Services | 1 | 2018 | 6 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 17 | 0.040 |
Why?
| | Urban Population | 1 | 2018 | 27 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 45 | 0.040 |
Why?
| | Algorithms | 1 | 2019 | 105 | 0.040 |
Why?
| | Medical Records | 1 | 2018 | 14 | 0.040 |
Why?
| | Sex Factors | 1 | 2018 | 68 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 35 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 23 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2018 | 30 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 39 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2018 | 29 | 0.040 |
Why?
| | Health Resources | 1 | 2018 | 17 | 0.040 |
Why?
| | Rural Population | 1 | 2018 | 42 | 0.040 |
Why?
| | Research Design | 1 | 2018 | 63 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 55 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2017 | 15 | 0.040 |
Why?
| | Cost of Illness | 1 | 2018 | 19 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2018 | 215 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 35 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 94 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2017 | 2 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2018 | 71 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 8 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2017 | 6 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 17 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 10 | 0.030 |
Why?
| | Tablets | 1 | 2016 | 1 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2016 | 17 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 14 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 42 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 6 | 0.030 |
Why?
| | Linezolid | 1 | 2014 | 2 | 0.030 |
Why?
| | Data Collection | 1 | 2014 | 29 | 0.030 |
Why?
| | Food Parasitology | 1 | 2011 | 1 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 33 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 18 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2011 | 11 | 0.020 |
Why?
| | Population Surveillance | 1 | 2011 | 13 | 0.020 |
Why?
| | Income | 1 | 2011 | 17 | 0.020 |
Why?
| | Risk-Taking | 1 | 2010 | 11 | 0.020 |
Why?
| | Insurance, Health | 1 | 2008 | 16 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|